Nkarta vs Vera Therapeutics
NKTX and VERA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NKTX and VERA compare
Vera Therapeutics is the larger company, worth 24 times as much as Nkarta ($2.0B against $85.2M).
Nkarta scores higher on the StockData Score (7 against 2 for Vera Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NKTX | VERA |
|---|---|---|
| Size and price | ||
| Market cap | $85.2M | $2.0B |
| Share price | $1.19 | $28.10 |
| Change, 1 year | −39.3% | −9.6% |
| Change, 5 years | −93.1% | −9.9% |
| Beta (5Y) | 1.18 | 0.82 |
| Employees | 108 | 249 |
| StockData Score | ||
| Total score | 7 (better) | 2 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.4× (better) | 6.1× |
| FCF yield | −120% | −18.6% (better) |
| Profitability | ||
| Return on equity | −46.6% (better) | −113% |
| Return on invested capital | −194% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −57.4× |
| Current ratio | 5.79 | 7.91 (better) |
| Altman Z-score | −3.83 | 3.87 (better) |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 82.9% | 108% |
| Held by insiders | 35.8% | 14.9% |
| Insider net buying, 12 months | −$70.4K (better) | −$11.5M |
| Short interest, % of float | 8.3% | 19.8% |
Go deeper
- NKTX stock overview
- NKTX income statement
- NKTX valuation and score
- VERA stock overview
- VERA income statement
- VERA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.